Regenerative Medicine Pioneer, TissueTech, Rebrands

One of the most important pioneering biologics firms in the United States (which, really, has not received its due in the world of regenerative medicine), Miami, Florida-based TissueTech, Inc., is now renamed, re-branded and, perhaps even “reborn” as BioTissue, Inc. The newly renamed company will include Amniox Medical, Inc.

“For years, health care professionals have known our products—regardless of their specific applications—for providing mother nature’s most natural gift of healing so their patients can get back to the lives they love,” said Ted Davis, BioTissue president and CEO. “Our new, unified brand supports our entire pipeline of human birth tissue products to aid the treatment of wounds, musculoskeletal conditions, trauma-induced injuries, ocular surface disease, and burns.”

The company’s amniotic membrane products retain their brand names, including Prokera, AmnioGraft, AmnioGuard, Neox, and Clarix. All these products use the company’s proprietary CryoTek cryopreservation technology.

“By combining our efforts behind a single brand and leveraging our collective strengths, the new BioTissue paves the way for more innovative research and development, collaboration with additional healthcare sectors, and a strong pipeline of future products,” said Davis, who recently took leadership of the company upon the retirement of Amy Tseng, BioTissue’s founder and former CEO. “As we look to the future of BioTissue, there are more great things to come.”

BioTissue says that its news includes a bold new design representing “healing, energy, and life.” And according to the company, additional branding is in the works, including a new website, conference/exhibit booth, and customer-facing support materials.

Asked what led to this change, Davis told OTW, “At BioTissue, we are continuously innovating to solve patients’ unmet clinical needs. Pushing the boundaries to set the standard for regenerative medicine has resulted in evolution in not only our products, but in our company.”

“As we pursue FDA approval for new products across surgical and ocular indications, a unified brand supports our entire portfolio of human birth tissue-based products which was born of a life-changing need—to help physicians as healers treat ocular surface diseases, wounds, and chronic pain in their patients with unprecedented efficacy. As we look to the future, it makes sense to operate under one unified brand. The BioTissue brand not only represents our current service and product portfolio, but also our innovation efforts across all applications. BioTissue is intuitive for what our products are all about and what we are doing in the space of regenerative medicine.

When OTW asked how having a single brand might play out over the next year, Davis notes, “For our customers, the transition to BioTissue is intended to be seamless. The products physicians rely on for their patients will not change; they’ll even keep their trusted brand names, including Prokera, Neox, and Clarix. The BioTissue brand allows us to confidently serve the regenerative medicine space with a trusted name that makes sense—now and into the future. We’re excited about what is ahead.”